Ocugen, Inc. (OCGN)
1.36
+0.01
(+0.74%)
USD |
NASDAQ |
Sep 04, 16:00
1.36
0.00 (0.00%)
After-Hours: 20:00
Ocugen Research and Development Expense (Quarterly) : 10.69M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 10.69M |
| March 31, 2026 | 11.26M |
| December 31, 2025 | 10.67M |
| September 30, 2025 | 10.20M |
| June 30, 2025 | 7.475M |
| March 31, 2025 | 9.529M |
| December 31, 2024 | 8.29M |
| September 30, 2024 | 8.108M |
| June 30, 2024 | 8.324M |
| March 31, 2024 | 6.826M |
| December 31, 2023 | 7.60M |
| September 30, 2023 | 7.048M |
| June 30, 2023 | 14.57M |
| March 31, 2023 | 10.17M |
| December 31, 2022 | 17.05M |
| September 30, 2022 | 15.62M |
| June 30, 2022 | 9.007M |
| March 31, 2022 | 7.915M |
| December 31, 2021 | 7.102M |
| September 30, 2021 | 6.281M |
| June 30, 2021 | 18.85M |
| March 31, 2021 | 2.872M |
| December 31, 2020 | 1.571M |
| September 30, 2020 | 8.077M |
| June 30, 2020 | 1.136M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.652M |
| December 31, 2019 | 1.747M |
| September 30, 2019 | 1.306M |
| June 30, 2019 | 1.24M |
| March 31, 2019 | 3.793M |
| December 31, 2018 | 2.916M |
| September 30, 2018 | 1.561M |
| June 30, 2018 | 4.458M |
| March 31, 2018 | 3.286M |
| December 31, 2017 | 3.366M |
| September 30, 2017 | 3.488M |
| June 30, 2017 | 4.208M |
| March 31, 2017 | 4.504M |
| December 31, 2016 | 5.317M |
| September 30, 2016 | 4.88M |
| June 30, 2016 | 5.794M |
| March 31, 2016 | 5.586M |
| December 31, 2015 | 5.773M |
| September 30, 2015 | 5.848M |
| June 30, 2015 | 5.858M |
| March 31, 2015 | 5.764M |
| December 31, 2014 | 4.576M |
| September 30, 2014 | 13.24M |
| June 30, 2014 | 4.696M |
| March 31, 2014 | 3.347M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Anika Therapeutics, Inc. | 7.341M |
| Gilead Sciences, Inc. | 1.69B |
| MannKind Corp. | 18.00M |
| Vertex Pharmaceuticals, Inc. | 993.80M |